tiprankstipranks
Voyager Therapeutics selects VY1706 for program in Alzheimer’s Disease
PremiumThe FlyVoyager Therapeutics selects VY1706 for program in Alzheimer’s Disease
2M ago
Voyager Therapeutics Reports Strong Q3 2024 Progress
Premium
Company Announcements
Voyager Therapeutics Reports Strong Q3 2024 Progress
2M ago
Voyager has sufficient resources for planned operating expenses into 2027
Premium
The Fly
Voyager has sufficient resources for planned operating expenses into 2027
2M ago
Voyager advances Neurocrine collaboration, selects third gene therapy candidate
PremiumThe FlyVoyager advances Neurocrine collaboration, selects third gene therapy candidate
4M ago
Voyager Therapeutics enters license for capsid
Premium
The Fly
Voyager Therapeutics enters license for capsid
5M ago
Voyager Therapeutics price target lowered to $7 from $8 at Wedbush
Premium
The Fly
Voyager Therapeutics price target lowered to $7 from $8 at Wedbush
6M ago
Voyager announces first participants dosed in Phase 1 SAD trial of VY-TAU01
PremiumThe FlyVoyager announces first participants dosed in Phase 1 SAD trial of VY-TAU01
8M ago
Voyager Therapeutics price target lowered to $8 from $10 at Wedbush
Premium
The Fly
Voyager Therapeutics price target lowered to $8 from $10 at Wedbush
8M ago
Voyager Therapeutics reports Q1 EPS (20c), consensus (44c)
Premium
The Fly
Voyager Therapeutics reports Q1 EPS (20c), consensus (44c)
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100